Drug firmBoehringer Ingelheim (India) on Wednesday said it has received approval from the Drugs Controller General of India(DCGI) for Nintedanib used for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.
Following the United States Food and Drug Administration (USFDA)'s approval in September 2019, Nintedanib in SSc-ILD has so far been approved in 15 countries including the European Union, Canada, Japan and Brazil, Boehringer Ingelheim (India) said in a statement.
"Systemic sclerosis is a life-altering condition and Nintedanib is the first and only approved treatment for SSc-ILD, serving a high unmet need making a real positive difference. For the treatment of people living with SSc-ILD, this is a quantum leap," Boehringer Ingelheim India MDSharad Tyagi said.
The DCGI approval is a milestone in Boehringer Ingelheim's dedication towards providing the best possible treatment for people living with SSc-ILD in India, he added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app